Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons.
Identifieur interne : 000153 ( Main/Exploration ); précédent : 000152; suivant : 000154Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons.
Auteurs : Jesús Castilla [Espagne] ; Ana Navascués [Espagne] ; Mirian Fernández-Alonso [Espagne] ; Gabriel Reina [Espagne] ; Francisco Pozo [Espagne] ; Itziar Casado [Espagne] ; Marcela Guevara [Espagne] ; Iván Martínez-Baz [Espagne] ; Aurelio Barricarte [Espagne] ; Carmen Ezpeleta [Espagne]Source :
- Vaccine [ 1873-2518 ] ; 2016.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Espagne (épidémiologie), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (épidémiologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Saisons (MeSH), Sous-type H1N1 du virus de la grippe A (MeSH), Sous-type H3N2 du virus de la grippe A (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Surveillance sentinelle (MeSH), Vaccination (statistiques et données numériques), Vaccins antigrippaux (usage thérapeutique), Vaccins sous-unitaires (usage thérapeutique), Virus influenza B (MeSH), Études cas-témoins (MeSH).
- MESH :
- prévention et contrôle : Grippe humaine.
- statistiques et données numériques : Vaccination.
- usage thérapeutique : Vaccins antigrippaux, Vaccins sous-unitaires.
- épidémiologie : Espagne, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Jeune adulte, Mâle, Saisons, Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Sujet âgé, Sujet âgé de 80 ans ou plus, Surveillance sentinelle, Virus influenza B, Études cas-témoins.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Case-Control Studies (MeSH), Child (MeSH), Child, Preschool (MeSH), Female (MeSH), Humans (MeSH), Influenza A Virus, H1N1 Subtype (MeSH), Influenza A Virus, H3N2 Subtype (MeSH), Influenza B virus (MeSH), Influenza Vaccines (therapeutic use), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male (MeSH), Middle Aged (MeSH), Seasons (MeSH), Sentinel Surveillance (MeSH), Spain (epidemiology), Vaccination (statistics & numerical data), Vaccines, Subunit (therapeutic use), Young Adult (MeSH).
- MESH :
- chemical , therapeutic use : Influenza Vaccines, Vaccines, Subunit.
- geographic , epidemiology : Spain.
- epidemiology : Influenza, Human.
- prevention & control : Influenza, Human.
- statistics & numerical data : Vaccination.
- Adolescent, Adult, Aged, Aged, 80 and over, Case-Control Studies, Child, Child, Preschool, Female, Humans, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus, Male, Middle Aged, Seasons, Sentinel Surveillance, Young Adult.
Abstract
BACKGROUND
In Navarra, Spain, subunit vaccine was first used in the 2014-2015 season, whereas trivalent split-virion influenza vaccines had been used in previous seasons. We estimate the effectiveness of the subunit vaccine in the current season and split vaccine in the two previous seasons against laboratory-confirmed influenza in the 2014-2015 season.
METHODS
Patients with influenza-like illness hospitalized or attended by sentinel general practitioners were swabbed for influenza testing. The previous and current vaccine status of laboratory-confirmed cases was compared to test-negative controls.
RESULTS
Among 1213 patients tested, 619 (51%) were confirmed for influenza virus: 52% influenza A(H3N2), 46% influenza B, and 2% A(H1N1)pdm09. The overall effectiveness for subunit vaccination in the current season was 19% (95% confidence interval [CI]: -13 to 42), 2% (95%CI: -47 to 35) against influenza A(H3N2) and 32% (95%CI: -4 to 56) against influenza B. The effectiveness against any influenza was 67% (95%CI: 17-87) for 2012-2013 and 2013-2014 vaccination only, 42% (95%CI: -31 to 74) for 2014-2015 vaccination only, and 38% (95%CI: 8-58) for vaccination in the 2012-2013, 2013-2014 and 2014-2015 seasons. The same estimates against influenza A(H3N2) were 47% (95%CI: -60 to 82), -54% (95%CI: -274 to 37) and 28% (95%CI: -17 to 56), and against influenza B were 82% (95%CI: 19-96), 93% (95%CI: 45-99) and 43% (95%CI: 5-66), respectively.
CONCLUSION
These results suggest a considerable residual protection of split vaccination in previous seasons, low overall effectiveness of current season subunit vaccination, and possible interference between current subunit and previous split vaccines.
DOI: 10.1016/j.vaccine.2016.01.054
PubMed: 26854911
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons.</title><author><name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain. Electronic address: jcastilc@navarra.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:regionArea><wicri:noRegion>Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:noRegion></affiliation></author><author><name sortKey="Navascues, Ana" sort="Navascues, Ana" uniqKey="Navascues A" first="Ana" last="Navascués">Ana Navascués</name><affiliation wicri:level="1"><nlm:affiliation>Complejo Hospitalario de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Complejo Hospitalario de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Fernandez Alonso, Mirian" sort="Fernandez Alonso, Mirian" uniqKey="Fernandez Alonso M" first="Mirian" last="Fernández-Alonso">Mirian Fernández-Alonso</name><affiliation wicri:level="1"><nlm:affiliation>Clínica Universidad de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Clínica Universidad de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Reina, Gabriel" sort="Reina, Gabriel" uniqKey="Reina G" first="Gabriel" last="Reina">Gabriel Reina</name><affiliation wicri:level="1"><nlm:affiliation>Clínica Universidad de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Clínica Universidad de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name><affiliation wicri:level="1"><nlm:affiliation>Centro Nacional de Microbiología (WHO National Influenza Centre-Madrid), Instituto de Salud Carlos III, Majadahonda, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro Nacional de Microbiología (WHO National Influenza Centre-Madrid), Instituto de Salud Carlos III, Majadahonda</wicri:regionArea><wicri:noRegion>Majadahonda</wicri:noRegion></affiliation></author><author><name sortKey="Casado, Itziar" sort="Casado, Itziar" uniqKey="Casado I" first="Itziar" last="Casado">Itziar Casado</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:regionArea><wicri:noRegion>Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:noRegion></affiliation></author><author><name sortKey="Guevara, Marcela" sort="Guevara, Marcela" uniqKey="Guevara M" first="Marcela" last="Guevara">Marcela Guevara</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:regionArea><wicri:noRegion>Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:noRegion></affiliation></author><author><name sortKey="Martinez Baz, Ivan" sort="Martinez Baz, Ivan" uniqKey="Martinez Baz I" first="Iván" last="Martínez-Baz">Iván Martínez-Baz</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:regionArea><wicri:noRegion>Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:noRegion></affiliation></author><author><name sortKey="Barricarte, Aurelio" sort="Barricarte, Aurelio" uniqKey="Barricarte A" first="Aurelio" last="Barricarte">Aurelio Barricarte</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:regionArea><wicri:noRegion>Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:noRegion></affiliation></author><author><name sortKey="Ezpeleta, Carmen" sort="Ezpeleta, Carmen" uniqKey="Ezpeleta C" first="Carmen" last="Ezpeleta">Carmen Ezpeleta</name><affiliation wicri:level="1"><nlm:affiliation>Complejo Hospitalario de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Complejo Hospitalario de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26854911</idno><idno type="pmid">26854911</idno><idno type="doi">10.1016/j.vaccine.2016.01.054</idno><idno type="wicri:Area/Main/Corpus">00146</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00146</idno><idno type="wicri:Area/Main/Curation">000146</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000146</idno><idno type="wicri:Area/Main/Exploration">000146</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons.</title><author><name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain. Electronic address: jcastilc@navarra.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:regionArea><wicri:noRegion>Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:noRegion></affiliation></author><author><name sortKey="Navascues, Ana" sort="Navascues, Ana" uniqKey="Navascues A" first="Ana" last="Navascués">Ana Navascués</name><affiliation wicri:level="1"><nlm:affiliation>Complejo Hospitalario de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Complejo Hospitalario de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Fernandez Alonso, Mirian" sort="Fernandez Alonso, Mirian" uniqKey="Fernandez Alonso M" first="Mirian" last="Fernández-Alonso">Mirian Fernández-Alonso</name><affiliation wicri:level="1"><nlm:affiliation>Clínica Universidad de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Clínica Universidad de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Reina, Gabriel" sort="Reina, Gabriel" uniqKey="Reina G" first="Gabriel" last="Reina">Gabriel Reina</name><affiliation wicri:level="1"><nlm:affiliation>Clínica Universidad de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Clínica Universidad de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name><affiliation wicri:level="1"><nlm:affiliation>Centro Nacional de Microbiología (WHO National Influenza Centre-Madrid), Instituto de Salud Carlos III, Majadahonda, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro Nacional de Microbiología (WHO National Influenza Centre-Madrid), Instituto de Salud Carlos III, Majadahonda</wicri:regionArea><wicri:noRegion>Majadahonda</wicri:noRegion></affiliation></author><author><name sortKey="Casado, Itziar" sort="Casado, Itziar" uniqKey="Casado I" first="Itziar" last="Casado">Itziar Casado</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:regionArea><wicri:noRegion>Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:noRegion></affiliation></author><author><name sortKey="Guevara, Marcela" sort="Guevara, Marcela" uniqKey="Guevara M" first="Marcela" last="Guevara">Marcela Guevara</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:regionArea><wicri:noRegion>Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:noRegion></affiliation></author><author><name sortKey="Martinez Baz, Ivan" sort="Martinez Baz, Ivan" uniqKey="Martinez Baz I" first="Iván" last="Martínez-Baz">Iván Martínez-Baz</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:regionArea><wicri:noRegion>Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:noRegion></affiliation></author><author><name sortKey="Barricarte, Aurelio" sort="Barricarte, Aurelio" uniqKey="Barricarte A" first="Aurelio" last="Barricarte">Aurelio Barricarte</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:regionArea><wicri:noRegion>Spain; CIBER Epidemiología y Salud Pública (CIBERESP)</wicri:noRegion></affiliation></author><author><name sortKey="Ezpeleta, Carmen" sort="Ezpeleta, Carmen" uniqKey="Ezpeleta C" first="Carmen" last="Ezpeleta">Carmen Ezpeleta</name><affiliation wicri:level="1"><nlm:affiliation>Complejo Hospitalario de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Complejo Hospitalario de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Case-Control Studies (MeSH)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (MeSH)</term><term>Influenza A Virus, H3N2 Subtype (MeSH)</term><term>Influenza B virus (MeSH)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Seasons (MeSH)</term><term>Sentinel Surveillance (MeSH)</term><term>Spain (epidemiology)</term><term>Vaccination (statistics & numerical data)</term><term>Vaccines, Subunit (therapeutic use)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Espagne (épidémiologie)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Saisons (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (MeSH)</term><term>Sous-type H3N2 du virus de la grippe A (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Surveillance sentinelle (MeSH)</term><term>Vaccination (statistiques et données numériques)</term><term>Vaccins antigrippaux (usage thérapeutique)</term><term>Vaccins sous-unitaires (usage thérapeutique)</term><term>Virus influenza B (MeSH)</term><term>Études cas-témoins (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Subunit</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins sous-unitaires</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza B virus</term><term>Male</term><term>Middle Aged</term><term>Seasons</term><term>Sentinel Surveillance</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Saisons</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Surveillance sentinelle</term><term>Virus influenza B</term><term>Études cas-témoins</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>In Navarra, Spain, subunit vaccine was first used in the 2014-2015 season, whereas trivalent split-virion influenza vaccines had been used in previous seasons. We estimate the effectiveness of the subunit vaccine in the current season and split vaccine in the two previous seasons against laboratory-confirmed influenza in the 2014-2015 season.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Patients with influenza-like illness hospitalized or attended by sentinel general practitioners were swabbed for influenza testing. The previous and current vaccine status of laboratory-confirmed cases was compared to test-negative controls.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Among 1213 patients tested, 619 (51%) were confirmed for influenza virus: 52% influenza A(H3N2), 46% influenza B, and 2% A(H1N1)pdm09. The overall effectiveness for subunit vaccination in the current season was 19% (95% confidence interval [CI]: -13 to 42), 2% (95%CI: -47 to 35) against influenza A(H3N2) and 32% (95%CI: -4 to 56) against influenza B. The effectiveness against any influenza was 67% (95%CI: 17-87) for 2012-2013 and 2013-2014 vaccination only, 42% (95%CI: -31 to 74) for 2014-2015 vaccination only, and 38% (95%CI: 8-58) for vaccination in the 2012-2013, 2013-2014 and 2014-2015 seasons. The same estimates against influenza A(H3N2) were 47% (95%CI: -60 to 82), -54% (95%CI: -274 to 37) and 28% (95%CI: -17 to 56), and against influenza B were 82% (95%CI: 19-96), 93% (95%CI: 45-99) and 43% (95%CI: 5-66), respectively.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>These results suggest a considerable residual protection of split vaccination in previous seasons, low overall effectiveness of current season subunit vaccination, and possible interference between current subunit and previous split vaccines.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26854911</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2016</Year><Month>02</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>11</Issue><PubDate><Year>2016</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons.</ArticleTitle><Pagination><MedlinePgn>1350-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2016.01.054</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(16)00117-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In Navarra, Spain, subunit vaccine was first used in the 2014-2015 season, whereas trivalent split-virion influenza vaccines had been used in previous seasons. We estimate the effectiveness of the subunit vaccine in the current season and split vaccine in the two previous seasons against laboratory-confirmed influenza in the 2014-2015 season.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with influenza-like illness hospitalized or attended by sentinel general practitioners were swabbed for influenza testing. The previous and current vaccine status of laboratory-confirmed cases was compared to test-negative controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 1213 patients tested, 619 (51%) were confirmed for influenza virus: 52% influenza A(H3N2), 46% influenza B, and 2% A(H1N1)pdm09. The overall effectiveness for subunit vaccination in the current season was 19% (95% confidence interval [CI]: -13 to 42), 2% (95%CI: -47 to 35) against influenza A(H3N2) and 32% (95%CI: -4 to 56) against influenza B. The effectiveness against any influenza was 67% (95%CI: 17-87) for 2012-2013 and 2013-2014 vaccination only, 42% (95%CI: -31 to 74) for 2014-2015 vaccination only, and 38% (95%CI: 8-58) for vaccination in the 2012-2013, 2013-2014 and 2014-2015 seasons. The same estimates against influenza A(H3N2) were 47% (95%CI: -60 to 82), -54% (95%CI: -274 to 37) and 28% (95%CI: -17 to 56), and against influenza B were 82% (95%CI: 19-96), 93% (95%CI: 45-99) and 43% (95%CI: 5-66), respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results suggest a considerable residual protection of split vaccination in previous seasons, low overall effectiveness of current season subunit vaccination, and possible interference between current subunit and previous split vaccines.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castilla</LastName><ForeName>Jesús</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain. Electronic address: jcastilc@navarra.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navascués</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Complejo Hospitalario de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández-Alonso</LastName><ForeName>Mirian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clínica Universidad de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reina</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clínica Universidad de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozo</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centro Nacional de Microbiología (WHO National Influenza Centre-Madrid), Instituto de Salud Carlos III, Majadahonda, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casado</LastName><ForeName>Itziar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guevara</LastName><ForeName>Marcela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Baz</LastName><ForeName>Iván</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barricarte</LastName><ForeName>Aurelio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezpeleta</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Complejo Hospitalario de Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Primary Health Care Sentinel Network</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Network for Influenza Surveillance in Hospitals of Navarra</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018571" MajorTopicYN="N">Sentinel Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">Influenza vaccine</Keyword><Keyword MajorTopicYN="N">Split-virion vaccine</Keyword><Keyword MajorTopicYN="N">Subunit vaccine</Keyword><Keyword MajorTopicYN="N">Vaccine effectiveness</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>01</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26854911</ArticleId><ArticleId IdType="pii">S0264-410X(16)00117-1</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2016.01.054</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country></list><tree><country name="Espagne"><noRegion><name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name></noRegion><name sortKey="Barricarte, Aurelio" sort="Barricarte, Aurelio" uniqKey="Barricarte A" first="Aurelio" last="Barricarte">Aurelio Barricarte</name><name sortKey="Casado, Itziar" sort="Casado, Itziar" uniqKey="Casado I" first="Itziar" last="Casado">Itziar Casado</name><name sortKey="Ezpeleta, Carmen" sort="Ezpeleta, Carmen" uniqKey="Ezpeleta C" first="Carmen" last="Ezpeleta">Carmen Ezpeleta</name><name sortKey="Fernandez Alonso, Mirian" sort="Fernandez Alonso, Mirian" uniqKey="Fernandez Alonso M" first="Mirian" last="Fernández-Alonso">Mirian Fernández-Alonso</name><name sortKey="Guevara, Marcela" sort="Guevara, Marcela" uniqKey="Guevara M" first="Marcela" last="Guevara">Marcela Guevara</name><name sortKey="Martinez Baz, Ivan" sort="Martinez Baz, Ivan" uniqKey="Martinez Baz I" first="Iván" last="Martínez-Baz">Iván Martínez-Baz</name><name sortKey="Navascues, Ana" sort="Navascues, Ana" uniqKey="Navascues A" first="Ana" last="Navascués">Ana Navascués</name><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name><name sortKey="Reina, Gabriel" sort="Reina, Gabriel" uniqKey="Reina G" first="Gabriel" last="Reina">Gabriel Reina</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000153 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000153 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26854911
|texte= Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26854911" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |